Last reviewed · How we verify
GSK2110183 in combination with carboplatin and paclitaxel
GSK2110183 in combination with carboplatin and paclitaxel is a Small molecule drug developed by Accenture. It is currently in Phase 1 development. Also known as: Taxol (paclitaxel), Paraplatin (carboplatin), AKT Inhibitor.
At a glance
| Generic name | GSK2110183 in combination with carboplatin and paclitaxel |
|---|---|
| Also known as | Taxol (paclitaxel), Paraplatin (carboplatin), AKT Inhibitor |
| Sponsor | Accenture |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Dose-finding Study in Platinum-Resistant Ovarian Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK2110183 in combination with carboplatin and paclitaxel CI brief — competitive landscape report
- GSK2110183 in combination with carboplatin and paclitaxel updates RSS · CI watch RSS
- Accenture portfolio CI
Frequently asked questions about GSK2110183 in combination with carboplatin and paclitaxel
What is GSK2110183 in combination with carboplatin and paclitaxel?
GSK2110183 in combination with carboplatin and paclitaxel is a Small molecule drug developed by Accenture.
Who makes GSK2110183 in combination with carboplatin and paclitaxel?
GSK2110183 in combination with carboplatin and paclitaxel is developed by Accenture (see full Accenture pipeline at /company/accenture).
Is GSK2110183 in combination with carboplatin and paclitaxel also known as anything else?
GSK2110183 in combination with carboplatin and paclitaxel is also known as Taxol (paclitaxel), Paraplatin (carboplatin), AKT Inhibitor.
What development phase is GSK2110183 in combination with carboplatin and paclitaxel in?
GSK2110183 in combination with carboplatin and paclitaxel is in Phase 1.
Related
- Manufacturer: Accenture — full pipeline
- Also known as: Taxol (paclitaxel), Paraplatin (carboplatin), AKT Inhibitor
- Compare: GSK2110183 in combination with carboplatin and paclitaxel vs similar drugs
- Pricing: GSK2110183 in combination with carboplatin and paclitaxel cost, discount & access